The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Triapin 2.5mg/2.5mg prolonged release tablet



PCO Manufacturing Ltd.PPA0465/318/001

Main Information

Trade NameTriapin 2.5mg/2.5mg prolonged release tablet
Active SubstancesRamipril
Felodipine
Dosage FormProlonged-release tablet
Licence HolderPCO Manufacturing Ltd.
Licence NumberPPA0465/318/001

Group Information

ATC CodeC09BB ACE inhibitors and calcium channel blockers
C09BB05 ramipril and felodipine

Status

License statusWithdrawn
Withdrawn Date31/01/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis authorisation permits the holder to parallel-distribute only product authorised in Ireland under the product authorisation number PA0540/082/001.
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0032-052-024
Interchangeable List DocumentPDF of Interchangeable List
« Back